Our study is in partial agreement with Yan et al. [10], who confirmed that GBM with an IDH1 mutation had a median OS of 31 versus 34 months (our study), which was significantly better than the 15 versus 16 months (our study) in patients with wild-type IDH1 (log-rank p < 0.05). Here, IDH1 is linked to glioblastoma.